PARP1 and glioma: Follow-up studies confirmed the radiosensitizing effect of PARP1 inhibitors on S-phase cells not only in fibroblasts carrying capillary ataxia mutation genes (173) but also in human lung, breast, glioma, and head and neck cancer cells (106, 172, 174, 175).